The clinical setback has raised questions regarding whether the company provided shareholders with an accurate assessment of its mRNA oncology pipeline. For every $10,000 invested, shareholders saw roughly $713 in value vanish upon the news. The investigation, spearheaded by Levi & Korsinsky LLP, aims to determine if BioNTech issued misleading statements concerning the clinical prospects of its cancer immunotherapy programs.
In section Releases
BioNTech Faces Investor Investigation Following Failed Cancer Trial
A 7.13% decline in BioNTech SE shares has triggered a formal investigation by the firm SueWallSt. The drop followed the company's announcement that the Phase 2/3 AHEAD-MERIT clinical trial for its BNT113 oncology candidate failed to meet its primary endpoint of progression-free survival against pembrolizumab alone.
Legal representatives are currently reviewing claims on behalf of investors who purchased shares at prices that may have been artificially inflated by the company’s prior disclosures. Eligibility for potential recovery extends to both those who currently hold the stock and those who sold their positions during the market decline. The firm maintains that investors regardless of their residence are eligible to participate, provided the securities were purchased on U.S. exchanges.
Comments (0)
No comments yet. Be the first!